ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
Rhea-AI Summary
ACELYRIN, INC. (Nasdaq: SLRN) announced positive data from its Phase 1/2 clinical trial of lonigutamab for thyroid eye disease (TED) will be presented at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery. The presentation, titled 'Preliminary Safety, Efficacy, and Quality of Life Outcomes of Subcutaneous Lonigutamab from a Phase 1/2 Proof of Concept Study in Patients with Thyroid Eye Disease,' will take place on September 14, 2024, in Rotterdam, Netherlands.
Dr. Jwu Jin Khong will deliver the rapid-fire oral presentation. ACELYRIN's Chief Medical Officer, Dr. Shephard Mpofu, highlighted the potential of lonigutamab to improve clinical outcomes through rapid suppression of IGF-1 receptor signaling, achieving robust responses with low drug exposures. The company believes the data supports the potential for subcutaneously-delivered lonigutamab to provide deep and durable responses with convenient, self-administered dosing.
Positive
- Positive proof-of-concept data from Phase 1/2 clinical trial of lonigutamab for TED
- Potential for rapid suppression of IGF-1 receptor signaling with lonigutamab
- Possibility of achieving robust clinical responses with low drug exposures
- Potential for deep and durable responses with convenient, self-administered dosing
Negative
- None.
Insights
The preliminary data from ACELYRIN's Phase 1/2 trial of lonigutamab in thyroid eye disease (TED) shows promising results. The rapid suppression of IGF-1R signaling suggests potential for improved clinical outcomes with low drug exposures. This could be a significant advancement in TED treatment, offering deep and durable responses with convenient subcutaneous self-administration.
However, it's important to note that these are early-stage results. The efficacy, safety and quality of life outcomes need to be thoroughly evaluated in larger, late-stage trials. The potential for lonigutamab to outperform existing treatments or address unmet needs in TED management remains to be seen. Investors should closely monitor upcoming data presentations and future trial results to assess the drug's true potential in the competitive ophthalmology market.
While the announcement of positive proof-of-concept data is encouraging for ACELYRIN, it's important to temper expectations. This early-stage success doesn't guarantee approval or commercial viability. The TED market is competitive, with established treatments already available.
Investors should consider:
- The potential market size for TED treatments
- ACELYRIN's financial position and burn rate during clinical development
- The company's ability to advance lonigutamab through costly late-stage trials
- Potential partnerships or licensing deals that could offset development costs
Given the early stage of development, this news likely won't have an immediate significant impact on ACELYRIN's stock price. However, it does provide a positive signal for the company's pipeline and could attract investor interest in the long term.
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive data from its Phase 1/2 clinical trial of lonigutamab (an anti-insulin-like growth factor 1 receptor, or IGF-1R) in thyroid eye disease (TED) will be shared in a rapid-fire oral presentation at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) taking place from September 12-14, 2024 in Rotterdam, Netherlands. Details of the data presentation are as follows:
| Title: | “Preliminary Safety, Efficacy, and Quality of Life Outcomes of Subcutaneous Lonigutamab (Anti–Insulin-Like Growth Factor 1 Receptor [IGF-1R]) from a Phase 1/2 Proof of Concept Study in Patients with Thyroid Eye Disease (TED)” |
| Session Type: | Rapid-fire Oral Presentation |
| Abstract ID: | 24-330 |
| Date/Time: | Saturday, September 14, 2024; 3:45 – 3:50 PM CEST |
| Presenter: | Jwu Jin Khong, M.D. Ph.D., Clinical Senior Lecturer in the Department of Surgery at the University of Melbourne and Consulting Ophthalmologist at the Royal Victorian Eye and Ear Hospital and the Austin Hospital |
“The rapid suppression of IGF-1 receptor signaling observed with lonigutamab could potentially improve clinical outcomes for patients by achieving robust clinical responses with low drug exposures,” said Shephard (Shep) Mpofu, M.D., Chief Medical Officer of ACELYRIN. “Importantly, we believe these data are supportive of the potential for subcutaneously-delivered lonigutamab to provide deep and durable responses with convenient, self-administered dosing.”
About Lonigutamab
Lonigutamab is a humanized IgG1 monoclonal antibody targeting the IGF-1 receptor and is delivered subcutaneously. Relative to standard of care, lonigutamab binds to a distinct epitope, which results in internalization of the receptor within minutes, and in preclinical binding and functional laboratory assays, it has been shown to be 75-fold more potent. The characteristics of lonigutamab that enable subcutaneous delivery also enable the potential for longer-term, convenient dosing, which can potentially improve depth and durability of clinical response.
About ACELYRIN, INC.
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.
For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements regarding ACELYRIN’s ability to address unmet needs of patients, business plans and potential future benefits of our pipeline. These forward-looking statements are based on ACELYRIN’s current plans, objectives and projections, and are inherently subject to risks and uncertainties that may cause ACELYRIN’s actual results to materially differ from those anticipated in such forward-looking statements. Such risks and uncertainties include, without limitation, those associated with the successful completion of development and regulatory activities with respect to ACELYRIN’s product candidates, the risk that future results could differ materially and adversely from early clinical data, and other risks and uncertainties affecting ACELYRIN including those described from time to time under the caption “Risk Factors” and elsewhere in ACELYRIN’s current and future reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ACELYRIN undertakes no duty to update such information except as required under applicable law.
ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com
FAQ
What is the purpose of ACELYRIN's Phase 1/2 clinical trial for lonigutamab (SLRN)?
When and where will ACELYRIN (SLRN) present the lonigutamab clinical trial results?
What are the potential benefits of lonigutamab for thyroid eye disease patients according to ACELYRIN (SLRN)?
Who will present ACELYRIN's (SLRN) lonigutamab clinical trial data at the ESOPRS meeting?
